A meta-analysis of irinotecan or etoposide plus platinum in the first-line treatment of extensive small cell lung cancer
WANG Wenxian
LING Mingzhu
SONG Zhengbo
ZHANG Yiping
Abstract：Objective To assess the efficacy and safety of irinotecan plus platinum(IP) compared with etoposide plus plati?num(EP) regimens in patients with extensive small cell lung cancer(ED?SCLC). Methods We searched the Cochrane Library, Pubmed, Medline, CBM,CNKI,CBM and WanFang databases to collect the randomized controlled trials,in which IP regimen was com?pared with EP regimen as the first?line treatment of ED?SCLC published before May 2014. RevMan 5?2 software was used for meta?a?nalysis. Results Nine studies involving 2229 patients were included. The result of meta?analysis showed that in patients with ED?SCLC, IP regimen was better than EP regimen in one?year survival rate( OR=1?32, 95%CI:1?10~1?58, P=0?003) and there was no significant difference between the both groups in the effective rate(OR=1?13, 95%CI:0?90~1?41, P=0?29). In the aspect of safety, the major adverse event for IP was more digestive toxicities, whereas EP was associated with more hematologic toxicities. Con?clusion IP regimen shows more superiority and can be used as the first?line drug for ED?SCLC, who intoleranced to hematologic toxci?ties.
Keywords：Small-cell lung cancerIrinotecanEtoposideMeta analysis
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 36-41 )